Antimicrobial & antimicrobial resistance
Publication Date
December 12, 2017
Creator
Abstract
By 2050, it is expected that antimicrobial resistance (AMR) will overtake cancer to become the world’s biggest killer. As the pharmaceutical industry spends less on antibiotic research and development, universities have an increasing role to play. As part of this degree, my two research projects approach AMR from different angles. The first takes a traditional approach to AMR, and uses transposon mutagenesis to identify novel novobiocin resistance mechanisms in Klebsiella pneumoniae. The second takes a genotypic approach and explores the application of anti-virulence drugs, which inhibit IscR in Yersinia pseudotuberculosis to disarm rather than kill the bacteria. Diversification is essential for the development of novel antimicrobial strategies.
Item Type
ethesis
Thesis Type
MRes
Supervisors
Subjects (LC)
Associated Schools / Departments
School of Biosciences (UK)
eprints ID
48146
UoN Repository URI
Except where otherwise noted, this item's license is described as
File(s)![Thumbnail Image]()
Name
MRes. Thesis.pdf
Type
Full-text
Description
Examined
Size
2.9 MB
Format
Adobe PDF
Checksum (MD5)
91e41672aede887ea992fd83ad272ce7